Online inquiry

IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13739MR)

This product GTTS-WQ13739MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPTL3 gene. The antibody can be applied in Hypertriglyceridemia&Homozygous familial hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014495.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27329
UniProt ID Q9Y5C1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13739MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3396MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ12857MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ179MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ13867MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ14104MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ13138MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ4459MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ4874MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BTCT4465A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW